Антибактериальная терапия обострений хронической обструктивной болезни легких

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2014. www.goldcopd.org/.
2. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
3. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006; 5: 343–9.
4. O’Donnell DE, Parker CM. COPD exacerbations: Pathophysiology. Thorax 2006; 61: 354–61.
5. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
6. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 1998; 151: 1418–22.
7. Miravitlles M, Murio C, Guerrero T et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–55.
8. Celli BR, Barnes PJ. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–38.
9. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–7.
10. Seneff MG, Wagner DP, Wagner RP et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–7.
11. Connors AF, Jr., Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959–67.
12. Suissa S, Dell'aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–63.
13. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114–21.
14. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–15.
15. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
16. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355–65.
17. Anzueto A. The pathogenesis of acute infection in COPD. Breathe 2009; 5: 311–5.
18. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193–203.
19. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
20. Roede BM, Bresser P, El Moussaoui R et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect 2007; 13: 284–90.
21. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
22. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.
23. Dev D, Sankaran EWR, Cunnife J et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir Med 1998; 92: 664–7.
24. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский мед. журн. 2008; 13: 19–24.
25. Wilson R, Jones P, Schaberg T et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–42.
26. Woodhead M, Blasi F, Ewig S et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
27. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. http://www.pulmonology.ru/publications/guide.php
28. O’Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin N Am 2004; 18: 691–716.
29. Blasi F, Tarsia P,  Aliberti S et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Therap 2006; 19: 11–9.
30. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1994; 6: 592–9.
31. Козлов Р.С., Кречикова О.И., Сивая О.В. и др. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-I). Клин. микробиология и антимикроб. химиотерапия. 2002; 4 (3): 267–77.
32. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг: результаты многоцентровых проспективных исследований ПеГАС–I и ПеГАС–II. Клин. микробиология и антимикроб. химиотерапия. 2006; 8 (1): 33–47.
33. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. Группа исследователей проекта «ПеГАС». Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (4): 329–41.
34. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002; 1: 121–8.
35. Haverkamp W, Kruesmann F, Fritsch A et al. Update on the cardiac safety of moxifloxacin. Current Drug Safety 2012; 7: 149–63.
36. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. An analysis of 14 years of clinical data. Drugs R D 2012; 12: 71–100.
37. Wilson R et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–64.
38. Urueta-Robledo J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort. Respir Med 2006; 100: 1504–11.
39. Wilson R, Anzueto A, Miravitlles M et al. Moxifloxacin vs amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results. Eur Respir J 2012; 40: 17–27.
40. Chuchalin A, Zakharova M, Dokic D et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulmonary Medicine 2013; 13: 5.
41. Wilson R, Schentag JJ, Ball P, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24: 639–52.
42. O'Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J 2008; 15 (Suppl. A): 1A–8A.
43. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.
44. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.

С.Н.Авдеев

ФГБУ НИИ пульмонологии ФМБА России, Москва